A registry of every treatment sequence patients actually receive, with outcomes
Record, for every patient, the order of treatments and what happened, so that the most common sequences can be compared and the worst ones flagged.
Approved drugs multiply faster than sequencing trials. A national or multi-centre registry capturing line-by-line therapy and outcomes (as the Flatiron and Dutch cancer registries partly do) with a public dashboard of sequence performance would let clinicians see which sequences are common and which look poor, and give trialists the effect sizes needed to design randomised sequence trials.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
Pages like this
not linked directly; found by shared links- IdeaA real-world sequencing analysis within a year of every new approval
Shares ADC sequencing, Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.
- IdeaPayers cover off-label combinations only inside registry-randomised trials
Shares Registry-embedded randomisation of treatment order in routine care, Too many combinations to test, Real-world evidence.
- IdeaWatch routine care for drug combinations that quietly make cancer treatment worse
Shares Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.
- IdeaEmulate combination trials from real-world data to triage which ones to run
Shares Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.
- IdeaLinked prescribing and outcome data to find drug interactions with cancer therapy
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaWearable activity data as a validated real-world endpoint
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaNo mCODE, no payment: tie oncology reimbursement to a minimal structured record
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaGood practice standards and inspection for real-world data sources
Shares Weak real-world evidence and registries, Real-world evidence.